Scott J. Antonia, MD, PhD

home / authors / scott-j-antonia-md-phd

Articles

Dr. Antonia on Investigational Immunotherapy Combinations in Stage III NSCLC

June 21st 2019

Scott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses investigational immunotherapy combinations in stage III non–small cell lung cancer (NSCLC).

Dr. Antonia on the Promise of Immunotherapy in NSCLC

Scott J. Antonia, MD, PhD

May 29th 2019

Scott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses the promise of immunotherapy in patients with non–small cell lung cancer.

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Shailaja Raj MD;Gregory Springett MD PhD;Daniel Indelicato MD;Marilyn Bui, MD, PhD;Anthony Conley MD;Sergio Lavilla-Alonso PhD;Xiuhua Zhao MS;Dungsa Chen PhD;Randy Haysek MD;Ricardo Gonzalez MD;Douglas Letson MD;Steven Eric Finkelstein MD PhD;Alberto Chiappori MD;Dimitry Gabrilovitch MD PhD;Scott J. Antonia, MD, PhD

February 22nd 2018

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Dr. Antonia on Emerging Immunotherapies in Lung Cancer

Scott J. Antonia, MD, PhD

December 2nd 2016

Scott J. Antonia, MD, PhD, chair of the Department of Thoracic Oncology at Moffit Cancer Center, discusses immunotherapies that are emerging in the field of lung cancer.